Jules Bordet Institute, Brussels
Cardiac toxicity in breast cancer treated with doxorubicin and paclitaxel
Published in Women's Health Law Weekly, November 27th, 2005
"The psychological difficulty of accepting a mastectomy for locally advanced breast cancer (LABC) justifies the use of chemotherapy as neoadjuvant primary treatment. The aim of this prospective study was to assess the efficacy of the AT schedule neoadjuvantly administered in terms of response rates and survival in patients with LABC, with a special focus on cardiac toxicity," scientists in Belgium reported.
"All patients were treated by doxorubicin (60 mg/m2 i.v.) bolus followed by paclitaxel (200 mg/m2) as a 3-h infusion....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly
More Articles from Women's Health Law Weekly
- Bridgetech Holdings International, Inc.
Agreement signed with M.D. Anderson Cancer Center for emerging recurrent cervical cancer prognostic - Columbia Presbyterian Medical Center, New York
Angiogenic growth factors may attenuate erectile dysfunction in the rat penis - Glan Clwyd General Hospital, Denbighshire
Antenatal betamethasone reduces neonatal respiratory distress after elective C-section - U.S. Centers for Disease Control & Prevention
Chlamydia trachomatis linked to persistence of high-risk HPV types - AdMeTech Foundation
Cutting-edge imaging technologies could save men's lives; to drive point home, "Manogram" launched - American Association for Cancer Research
Updated data on novel HPV vaccine confirm its efficacy in large population - More from this issue of Women's Health Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
